Shanghai Henlius Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Groundbreaking HLX316 (B7-H3-Targeting Sialidase Fc Fusion Protein)
Shanghai Henlius Biotech, Inc. (HKEX: 2696) has made a significant announcement that could potentially impact its share valuation and attract considerable investor attention. The company has commenced dosing the first patient in a Phase 1 clinical study of its innovative drug candidate, HLX316, in Chinese Mainland patients with advanced or metastatic solid tumours.
Key Highlights of the Announcement
- First Patient Dosed: A major milestone was achieved as the first patient has been enrolled and dosed in the first-in-human Phase 1 clinical study of HLX316.
- Study Focus: HLX316 is a B7-H3-targeting sialidase Fc fusion protein, intended for the treatment of advanced/metastatic solid tumours.
- Geographic Scope: The study is being conducted in Mainland China, excluding Hong Kong, Macau, and Taiwan.
Clinical Trial Details
- Design: The trial is an open-label, first-in-human study to evaluate:
- Safety and tolerability
- Pharmacokinetic profiles
- Preliminary efficacy of HLX316
- Structure: The study consists of two stages:
- Phase 1a: Dose escalation and backfill, including five dose levels (1.0 mg/kg to 30.0 mg/kg) administered weekly. The lowest dose cohort uses an accelerated titration design, while the rest follow a traditional “3+3” escalation format. Dose backfill will occur at selected levels after safety evaluation.
- Phase 1b: Dose expansion at a level determined by safety and preliminary efficacy data from Phase 1a.
- Primary Objectives:
- Assess safety and tolerability
- Determine maximum tolerated dose (MTD)
- Identify recommended Phase 2 dose (RP2D)
- Preliminary assessment of anti-tumour efficacy
- Primary Endpoints: Incidence of dose-limiting toxicities, MTD and RP2D, and the objective response rate (ORR) as assessed by the investigator.
About HLX316: A Potentially Game-Changing Therapy
- Innovative Mechanism: HLX316 is a novel, first-in-class fusion protein combining:
- An engineered human sialidase Neu2 (with improved stability and manufacturability) fused to human IgG1 Fc region
- A heavy chain-only antibody variable region (VHH) targeting human B7-H3, also fused to human IgG1 Fc region
- Mode of Action: Targets B7-H3-expressing tumours, cleaves immunosuppressive sialylated glycans, enhances anti-tumour immune response, and avoids systemic immune activation.
- Preclinical Data: Shows strong antigen-directed desialylation, tumour growth inhibition in humanised mouse models, and potential therapeutic benefit for advanced solid tumours.
- Licensing and Development: The sialidase bifunctional fusion protein technology was licensed from Palleon Pharmaceuticals Inc. in May 2024.
- Regulatory Status: The IND application for HLX316 was approved by the National Medical Products Administration (NMPA) in March 2026.
Potential Market Impact and Shareholder Considerations
- First-in-Class Opportunity: As of the announcement date, no B7-H3-targeting sialidase Fc fusion protein has received marketing approval globally. If successful, HLX316 could represent a significant commercial and clinical breakthrough, potentially driving substantial value for Henlius.
- Risks and Uncertainties: The company cautions that successful development and commercialisation are not guaranteed. Shareholders should be aware of the early stage of development and the inherent uncertainties of clinical drug development, which can affect share price volatility.
Leadership and Governance
The announcement is made on behalf of the Board, chaired by Mr. Wenjie Zhang, with a diverse mix of executive, non-executive, and independent non-executive directors, ensuring robust governance and oversight.
Conclusion
The commencement of first-in-human dosing for HLX316 marks a critical inflection point for Shanghai Henlius Biotech. Investors should closely monitor further developments from this trial, as positive results could materially change the company’s market position and valuation.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. The successful development and commercialisation of HLX316 remain uncertain. Investors are urged to exercise caution when dealing in shares of Shanghai Henlius Biotech, as clinical and regulatory outcomes may materially impact the company’s valuation.
上海复宏汉霖宣布首例患者完成入組，開啟創新藥物HLX316第一期臨床試驗，或帶動股價波動
上海复宏汉霖股份有限公司（港交所：2696）公佈一項對股東及潛在投資者極具影響力的重要進展。公司最新創新藥物HLX316已於中國內地進行首例患者給藥，對象為晚期或轉移性實體腫瘤患者。
公告重點
- 首例患者入組並給藥：HLX316進入人體第一期臨床試驗，標誌里程碑式進展。
- 研究重點：HLX316為B7-H3靶向唾液酸酶Fc融合蛋白，研發目標為治療晚期/轉移性實體腫瘤。
- 地理覆蓋：試驗於中國內地進行，不包括香港、澳門及台灣。
臨床試驗詳情
- 設計：本為開放標籤、首次在人體進行的研究，評估HLX316之：
- 安全性及耐受性
- 藥代動力學特性
- 初步療效
- 結構：研究分兩階段：
- 第一期a：劑量遞增及回填階段，涵蓋五個劑量水平（1.0至30.0mg/kg），每週給藥。最低劑量採加速遞增設計，其餘採傳統“3+3”設計，回填根據安全數據決定。
- 第一期b：根據一期a的安全及初步療效數據，選擇劑量進行擴展試驗。
- 主要目標：
- 評估安全性及耐受性
- 確定最大耐受劑量（MTD）
- 確定二期推薦劑量（RP2D）
- 初步評估抗腫瘤療效
- 主要終點：包括劑量限制性毒性發生率、MTD及RP2D、客觀緩解率（ORR）。
HLX316介紹 — 潛力巨大新藥
- 創新機制：HLX316為首創雙功能融合蛋白，結合：
- 工程化人類唾液酸酶Neu2（增強穩定性及製備性）與人IgG1 Fc區融合
- 專一靶向人B7-H3的重鏈抗體VHH區，同樣與人IgG1 Fc區融合
- 作用機制：靶向B7-H3表達腫瘤，切割免疫抑制性唾液化糖鏈，增強抗腫瘤免疫反應，避免全身性免疫活化。
- 臨床前數據：體外顯示有力的抗原導向脫唾液酸作用，人源化小鼠模型中有效抑癌，對晚期實體腫瘤具潛力。
- 技術授權：唾液酸酶雙功能融合蛋白技術於2024年5月由Palleon Pharmaceuticals Inc.授權。
- 監管狀態：HLX316一期臨床的IND申請於2026年3月獲國家藥監局批准。
市場影響及股東需注意事項
- 全球首創：截至公告日，尚無任何B7-H3靶向唾液酸酶Fc融合蛋白藥物獲批。如HLX316成功，將具重大臨床及商業突破，有望大幅提升公司價值。
- 風險提示：公司明確表示不能保證新藥最終能成功開發及商品化。股東需認知項目處於初期階段，臨床研發不確定性高，可能導致股價波動。
公司管治
公告由張文傑董事長代表董事會發佈，董事會成員涵蓋執行、非執行及獨立非執行董事，管治結構完善。
總結
HLX316首次人體給藥標誌上海復宏漢霖在腫瘤創新藥研發路上的重要節點。投資者應密切關注後續臨床進展，因其結果有可能顯著影響公司市值及市場地位。
免責聲明
本文僅用作資訊參考，並非投資建議。HLX316能否成功開發及商品化存在不確定性。投資者買賣上海復宏漢霖股份時應審慎行事，臨床及監管結果可能對公司估值產生重大影響。
